EYPT, US30233G2093

EyePoint Pharmaceuticals stock closed at EUR 2.76, up 3.76 percent

Published on 10/17/2026 at 21:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

JonesTrading set USD 20.00 on September 29, 2026. EyePoint Pharmaceuticals stock closed EUR 2.76 in Frankfurt on October 16, 2026, up 3.76 percent.

Analyst target and reporting date

JonesTrading set a USD 20.00 target for EyePoint Pharmaceuticals on September 29, 2026.
EyePoint reported a GAAP net loss of USD 94.47 million for the quarter ended June 30, 2026.
EyePoint Pharmaceuticals stock closed at EUR 2.76 in Frankfurt on October 16, 2026, up 3.76 percent on the day.
EyePoint is estimated to report third-quarter results on November 4, 2026.

EYPT, US30233G2093, Illustration mit AI erstellt.

EyePoint Pharmaceuticals stock closed at EUR 2.76 in Frankfurt on October 16, 2026, up 3.76 percent on the day. The market is now weighing a wide analyst target gap against the company's continuing clinical investment.

According to The Globe and Mail on September 29, 2026, JonesTrading maintained a Buy rating and set a USD 20.00 price target. That target is materially above the Frankfurt closing price, but the report also identifies a broad range of analyst views.

Losses remain substantial

For the quarter ended June 30, 2026, EyePoint reported revenue of USD 507,000 and a GAAP net loss of USD 94.47 million, according to The Globe and Mail. Revenue was USD 5.33 million in the year-earlier quarter, while the prior-year GAAP net loss was USD 59.43 million, making the comparison unfavorable on both reported measures.

Clinical pipeline drives the outlook

EyePoint's investor-relations page describes DURAVYU as its lead product candidate and says the treatment is in global Phase 3 trials for wet age-related macular degeneration and diabetic macular edema. The page also lists topline LUGANO data released on August 17, 2026 and second-quarter results published on August 5, 2026, according to EyePoint.

Next results date is November 4

MarketBeat estimates that EyePoint will report third-quarter 2026 results on November 4, 2026, before the market opens, with a conference call scheduled for 8:30 a.m. ET. Its estimate calls for revenue of USD 0.23 million and adjusted earnings per share of minus USD 0.91.

Frankfurt price and market value

On Nasdaq, EyePoint last traded at USD 2.99 on October 16, 2026 at 4:00 p.m. ET. The company's market capitalization was USD 250.7 million on that date, while its 52-week Nasdaq range was USD 2.93 to USD 19.11. The Frankfurt closing price of EUR 2.76 therefore reflects a separate German-market quotation.

EyePoint's next major checkpoint is the November 4 reporting date, while DURAVYU trial progress remains central to the longer-term investment case.